The estimated Net Worth of Su Il Yum is at least $115 mil dollars as of 17 October 2012. Dr Yum owns over 73,454 units of Durect Corp stock worth over $115,323 and over the last 21 years he sold DRRX stock worth over $0.
Sign up
Dr D DRRX stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Durect Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 73,454 units of DRRX stock worth $57,294 on 17 October 2012.
The largest trade he's ever made was exercising 73,454 units of Durect Corp stock on 17 October 2012 worth over $57,294. On average, Dr trades about 4,897 units every 0 days since 2003. As of 17 October 2012 he still owns at least 73,454 units of Durect Corp stock.
You can see the complete history of Dr Yum stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Su Il Yum Ph.D. biography
Dr. Su Il Yum Ph.D. is the Exec. Officer at Durect Corp.
How old is Dr D?
Dr D is 82, he's been the Exec. Officer of Durect Corp since . There are no older and 5 younger executives at Durect Corp.
What's Dr D's mailing address?
Su's mailing address filed with the SEC is 10260 BUBB ROAD, , CUPERTINO, CA, 95014.
Insiders trading at Durect Corp
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management..., eFelix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
What does Durect Corp do?
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
What does Durect Corp's logo look like?
Complete history of Dr Yum stock trades at Durect Corp
Durect Corp executives and stock owners
Durect Corp executives and other stock owners filed with the SEC include:
-
Dr. James E. Brown D.V.M.,
Co-Founder, CEO, Pres & Director -
Michael H. Arenberg,
CFO & Sec. -
Dr. Norman L. Sussman,
Chief Medical Officer -
Judy R. Joice,
Sr. VP of Operations & Corp. Quality Assurance -
Dr. Su Il Yum Ph.D.,
Exec. Officer -
Jian Li M.B.A.,
VP of Fin. & Corp. Controller -
Dr. WeiQi Lin,
Exec. VP of R&D and Principal Scientist -
Steve Helmer J.D.,
VP & Chief Patent Counsel -
Dr. Andrew R. Miksztal,
VP of Pharmaceutical R&D and Principal Scientist -
Judy R Joice,
Sr. VP Operations & Corp QA -
April Fund Ltd21 April Fund...,
-
April Fund Ltd Arnhold & S....,
-
Dave Hoffmann,
Director -
Jon S Saxe,
Director -
Terrence F Blaschke,
Director -
Jay Shepard,
Director -
Armand Neukermans,
Director -
Simon X Benito,
Director -
Eagle Investment Management...,
-
April Fund Ltd21 April Fund...,
-
Matthew J Hogan,
Chief Financial Officer -
Michael Arenberg,
Chief Financial Officer -
Judith J. Robertson,
Director -
Gail M Farfel,
Director -
Paula V Mendenhall,
Sr. VP of Operations -
Su Il Yum,
Exec. VP Pharm./R&D -
Michael D Casey,
Director -
Joseph William Stauffer,
CMO and Exec.VP Corp. Strategy -
Jean I Liu,
Senior VP & General Counsel -
Edward M Gillis,
VP Engineering -
Thomas A Schreck,
Chief Financial Officer -
Michael J Taylor,
VP, Non Clinical Research -
Felix Theeuwes,
Chairman and CSO -
Arthur J Tipton,
Sr.VP Bioerodible Product Dev. -
Timothy S Nelson,
Senior VP Business & Dev. -
Peter Langecker,
Chief Medical Officer -
Tai Wah Chan,
VP Pharmaceutical Research -
Steven Halladay,
VP Clinical and Regulatory -
Li Jian,
VP Finance and Controller -
Lp Bleichroeder,
10% owner -
Eagle Investment Management...,
-
Mohammad Azab,
Director -
Gail J Maderis,
Director -
Peter S Garcia,
Director -
James E Brown,
President & CEO -
Timothy M. Papp,
Chief Financial Officer -
Norman Sussman,
Chief Medical Officer